Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Med-Tech Council Will Shorten Coverage Decision Process, Agency Says

This article was originally published in The Gray Sheet

Executive Summary

The feasibility of opening the Medicare benefit category determination process to public scrutiny will be explored by CMS' Medical Technology Council at its inaugural meeting in early April

You may also be interested in...



CMS Tech Council Implementation Requires Industry Involvement – Grissom

CMS' Council for Technology & Innovation will offer an unprecedented opportunity for device firms to help bring transparency to the agency - as long as industry assists in the panel's creation, Boston Scientific VP-Government Affairs Tom Grissom said at AdvaMed's annual meeting March 4

CMS Tech Council Implementation Requires Industry Involvement – Grissom

CMS' Council for Technology & Innovation will offer an unprecedented opportunity for device firms to help bring transparency to the agency - as long as industry assists in the panel's creation, Boston Scientific VP-Government Affairs Tom Grissom said at AdvaMed's annual meeting March 4

Device Industry Extols Medicare Passage Despite Competitive Bidding Thorn

AAHomecare plans to meet with CMS officials Dec. 3 to seek clarification on DME competitive bidding provisions in the Medicare reform bill, following whirlwind floor votes and last-minute negotiating

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel